Weiyue Lu

USPTO Granted Patents = 5 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

Shanghai Pharmco Research, Inc.

patent

1 out of 1

Shanghai Whittlong Pharmaceutical Institute

patent

Years Active: 2006-2023

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11826431 - Polypeptide-based ocular absorption enhancer and application thereof (2023-11-28),

2. 11622990 - VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor (2023-04-11),

3. 11260032 - Method for preparing biofilm-coated drug nanocrystal and application thereof (2022-03-01),

4. 11213591 - Polypeptide eye absorption enhancer and use thereof (2022-01-04),

5. 7005426 - Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component (2006-02-28),

Title: Weiyue Lu: Innovator in Pharmaceutical Preparations

Introduction

Weiyue Lu is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of pharmaceutical preparations. With a total of five patents to his name, Lu has focused on developing innovative solutions for ocular drug delivery and targeted cancer treatment.

Latest Patents

One of Lu's latest patents is titled "Polypeptide-based ocular absorption enhancer and application thereof." This invention pertains to the design of lipophilic derivatives using the wild-type penetrating peptide penetratin. These derivatives exhibit a strong ability to penetrate ocular tissues without causing toxicity. As ocular absorption enhancers, they facilitate non-invasive intraocular drug delivery, significantly improving the bioavailability of drugs for treating intraocular and fundus diseases. Another notable patent is "VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor." This invention features highly stable D-configuration polypeptides DVAP and SVAP, which have a high binding activity to the GRP78 protein. It also includes an L-configuration polypeptide LVAP and a modified model drug for constructing a tumor imaging and drug-delivery system aimed at targeted treatment.

Career Highlights

Weiyue Lu has worked with esteemed institutions such as Fudan University and Shanghai Pharmco Research, Inc. His work has been instrumental in advancing the field of drug delivery systems, particularly in enhancing the effectiveness of treatments for ocular diseases and cancer.

Collaborations

Lu has collaborated with notable professionals in his field, including Gang Wei and Kuan Jiang. These partnerships have contributed to the development of his innovative patents and research initiatives.

Conclusion

Weiyue Lu's contributions to pharmaceutical preparations highlight his role as a leading inventor in ocular drug delivery and cancer treatment. His innovative patents reflect a commitment to improving patient care and treatment efficacy.

This text is generated by artificial intelligence and may not be accurate.